A Next-Gen Candidate Built for Better Outcomes SureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs, positioning this up-and-coming microcap as a small but strategically focused company moving through the FDA process
Materials and methods GLP-1 peptides GLP-1 peptides, semaglutide (HY-114118, MedChemExpress, Monmouth Junction, NJ, USA), tirzepatide (39748, Cayman Chemical, Ann Arbor, Michigan, USA), and retatrutide (HY-P3506, MedChemExpress) were dissolved in saline (Otsuka Pharma, Tokushima, Japan)
The New Face of Creatine Creatine was once the stuff of sports legend, but it has begun to garner a broader following for several reasons, including its unique ability to prevent the loss of muscle mass a key concern for the growing number of individuals taking GLP-1 medications like Ozempic or Wegovy
Hou J, Tian L, Wei Y